Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Inocras closes $31 million in Series B-3 financing to accelerate U.S. commercial expansion.
PRIVATEAug 03, 2026•6 days ago
Amount Raised
$31 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareGenetics
Description
Inocras has successfully closed an oversubscribed Series B-3 financing round, raising $31 million. This funding will be utilized to support the company's commercial expansion efforts in the U.S. market. The round demonstrates strong investor confidence in Inocras's growth strategy and potential.
Company Information
Company
Inocras & Summit Pharmaceuticals International Corporation
Location
San Diego, California, United States
About
Inocras Inc. and Summit Pharmaceuticals International Corporation are collaborating to bring advanced whole genome sequencing (WGS) and bioinformatics services to Japan's healthcare system, aiming to better understand and treat genetic conditions, especially cancer.
Related People
Suggested for you
3 contacts
Verified contactsDavid D., Chief Commercial Officer (CCO) hidden hidden
Predictive Intelligence
Strategic
ML-powered predictions for Inocras & Summit Pharmaceuticals International Corporation's next move
San DiegoBiotechnologyHealth CareGenetics